Immunogenicity and safety of Gardasil among mid-adult aged men (27–45 years)—The MAM Study

Highlights • The quadrivalent HPV vaccine was administered to mid-adult men ages 27–45 years. • 100% of men seroconverted to each of the four HPV vaccine components. • Immune response to vaccine in men ages 27–45 was comparable to that in younger men. • Antibody response did not differ by age group...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2015-10, Vol.33 (42), p.5640-5646
Hauptverfasser:	Giuliano, Anna R, Isaacs-Soriano, Kimberly, Torres, B. Nelson, Abrahamsen, Martha, Ingles, Donna J, Sirak, Bradley A, Quiterio, Manuel, Lazcano-Ponce, Eduardo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Age Allergy and Immunology Antibodies, Neutralizing - blood Antibodies, Viral - blood Antibody Formation Biomedical research Cervical cancer FDA approval Florida HPV Human papillomavirus Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - administration & dosage Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - adverse effects Humans Immune response Immunogenicity Immunoglobulin G - blood Immunoglobulins Infections Male Mexico Mid-adult men Middle Aged Papillomavirus Infections - prevention & control Vaccine Vaccines Women
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • The quadrivalent HPV vaccine was administered to mid-adult men ages 27–45 years. • 100% of men seroconverted to each of the four HPV vaccine components. • Immune response to vaccine in men ages 27–45 was comparable to that in younger men. • Antibody response did not differ by age group or sexual orientation. • No serious adverse events attributable to vaccination were observed.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2015.08.072